eFoodSafety.com, Inc. Projects $10 Million in Revenue from the Sale of Diabetes Product, Cinnergen(TM).

SCOTTSDALE, Ariz. -- Patricia Ross-Gruden, President and Chief Executive Officer of eFoodSafety.com, Inc. (OTCBB: EFSF), announced today that the company is cautiously optimistic that revenues over the next 18 months will be approximately $10 million from the sale of Cinnergen(TM) (www.cinnergen.com), a product formulated to assist the body in metabolizing blood sugar.

Cinnergen(TM) is a once-a-day formula made from 15 whole foods that contain no fats, carbohydrates, sugar, or calories. Cinnergen(TM) is specially formulated to promote healthy glucose metabolism and to decrease the symptoms that commonly accompany elevated blood sugar and its effects. Cinnergen(TM) delivers concentrated nutrition to help the body efficiently and effectively metabolize sugar. As a whole food complex, Cinnergen provides several key ingredients that have been proven clinically through years of research to improve digestion and utilization of sugar, which are generally deficient in a typical American diet.

The total direct and indirect costs of diabetes in the United States as calculated in 2002 were estimated at $132 Billion and growing. Cinnergen(TM)'s all-natural formulation can supplement prescriptive medication in Type 1 diabetic patients, can supplement prescriptive medication and help decrease required levels of medication in Type 2 diabetic and borderline patients, and with regular use help normalize blood sugar levels and forestall pre-diabetic individuals from developing complications of high blood sugar.

The company currently has a Direct Response Marketing Campaign underway for the sale of Cinnergen(TM), with initial feedback being extremely positive. Based on initial sales and anticipated budgets, it is projected that $10 Million in sales are obtainable over the next 18 months.

"We are pleased to report to our shareholders the deliverance of worthwhile and exciting product offerings while we continue in our efforts to generate revenue and profitability to enhance shareholder value," stated Patricia Ross-Gruden, President and CEO of eFoodSafety.com, Inc.

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, and avian influenza. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration; in the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and Worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company has also recently become a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com).

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.